Teva Pharmaceutical Industries has presented promising data from a late-stage trial of a longer-acting version of its blockbuster multiple sclerosis drug Copaxone.
The Israeli drugmaker announced positive top-line results from a Phase III trial assessing 40 mg of Copaxone (glatiramer acetate) injection administered subcutaneously three times a week compared to placebo in relapsing-remitting MS patients. The one-year study, which recruited more than 1,400 patients, showed that the high dose met the study’s primary endpoint by significantly reducing the annualised relapse rate by 34.4% compared to placebo.
Teva added that initial analysis of the data indicates that secondary endpoints were achieved, with the exception of reduction in brain atrophy. Following the initial 12-month, placebo-controlled phase, there will be an ongoing open-label extension of the trial.
Copaxone is currently sold as a 20mg daily injection and is a huge earner. First-quarter sales reached $909 million, up 8%, and last month Teva said the drug should come in at around $3.80 billion. However oral MS drugs, notably Novartis' Gilenya, (fingolimod), are expected to eat into market share and Copaxone patents start to expire in the USA in 2014; if approved, the longer-acting version could help ward off these threats.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.